A liver headline that sounds almost too clean. So naturally, we're reading the fine print first. You're listening to GLP-1 Daily. Today: whose livers that result actually describes, and whether trading a weekly shot for a daily pill changes anything once insurance gets involved. Liver first. Who presented it, and how many people does it rest on? Follow the show and the next briefing lands in your feed on its own. Charlie King, writing in Medical Update Online:
Novo Nordisk presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes. Change in percentage of liver fat, determined by magnetic resonance imaging (MRI), showed that mean liver fat in the group taking semaglutide declined from 8.8% at baseline to 3.1% at week 72.
Nine in ten sounds like a crowd. It's twenty-three people. Twenty-three of the twenty-six who started above the five percent liver-fat line, inside a fifty-five-person MRI slice of STEP UP. Company-presented, post hoc, at EASD in Milan. And they pooled the 7.2 and the 2.4 milligram doses, so which dose drove 8.8 percent down to 3.1? Can't tell you. Compare ACHIEVE-4: built to answer one question, written up in the Lancet. Same month, completely different tier of evidence. What I keep looking at is who got scanned. Adults with obesity, no diabetes. That's the exact patient a coverage system keyed to a diabetes code sends away. But no payer's rewriting criteria off fifty-five people, and I wouldn't ask them to. Yeah, so what would move them? A prespecified liver endpoint, one dose, enough patients to see whether a cleaner scan actually means less liver disease years out. Meantime, if you're on Wegovy and wondering about your liver, ask for the check. Just don't treat a conference slide as a promise. Okay, so the FDA's approved a Wegovy pill. Is that basically the weekly shot minus the needle? And does it mean insurance is going to cover it? What changes right away is the route and the schedule. The FDA cleared Wegovy as a daily oral medication for obesity, which makes it the first oral GLP-1 drug approved for weight loss in the U.S., according to the Associated Press. The injectable Wegovy and Ozempic are semaglutide too, but you take those weekly. The tablet's every day. That could matter a lot if you'd rather not inject. But it comes with strings: U.S. News reports the pill needs a strict morning routine. It's approved for weight loss and for cardiovascular-risk reduction, and Novo Nordisk said it'd be widely available in January after the December FDA approval. Now, approval and availability don't settle things for any one patient. Prescribing still comes down to your clinician's assessment, and coverage, out-of-pocket cost and plan rules all vary. So if you're thinking about switching, it's a good time to ask your prescriber how that daily routine, the approved uses and your other options fit your own care. And on results, do we know if switching from the injection to the pill gets you the same long-term benefit? Or is that still open? Still open. Novo Nordisk presented a real-world analysis where people who switched from a Wegovy or Zepbound injection to the Wegovy pill, and stayed on treatment for three months, lost roughly 4% more weight. That's company-presented and short-term, so it won't settle the long-term comparison. For now, the pill gives patients one more FDA-approved option, and the things to watch are coverage decisions, how well people stick with a daily dose, and longer-term data after switching. Have feedback, a story idea, or a correction? Email us at glp1daily at lantern podcasts dot com. We'd love to hear from you.
Links to every story are in the show notes, so dig into whichever ones caught your eye when you get a minute. That's GLP-1 Daily for today. We'll be back tomorrow. This is a Lantern Podcast.